Pfizer has sold assets to Alvogen which include a portfolio of three injectable products and one inhaled solution product, as...
Allergan presented the results of its HARMONY study, which assessed the overall impact and psychological benefits of multimodal injectable and...
Eli Lilly and Company announced that the European Commission granted marketing authorisation for Trulicity (dulaglutide) solution for injection. Trulicity, a...
Fresenius Kabi announced it has been granted an expanded indication for SMOFlipid Lipid Injectable Emulsion (ILE) for pediatric patients in the United States, including term and preterm neonates, making it the first and only four-oil lipid emulsion for parenteral nutrition patients of every age.
Braeburn announces that Brixadi (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, is now available in the U.S.